TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Nykode Therapeutics ASA
Closing information (x1000 DKK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
5,466
|
8,554
|
5,064 |
| Financial expenses |
3,893
|
3,102
|
4,566 |
| Earnings before taxes |
-28,662
|
-29,231
|
-36,017 |
| Total assets |
96,654
|
138,034
|
156,461 |
| Current assets |
73,722
|
109,848
|
149,676 |
| Current liabilities |
5,730
|
13,664
|
27,541 |
| Equity capital |
85,781
|
113,551
|
110,924 |
| - share capital |
231
|
243
|
239 |
| Employees (average) | 139 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
88.8%
|
82.3%
|
70.9% |
| Turnover per employee | 39 | ||
| Profit as a percentage of turnover |
-524.4%
|
-341.7%
|
-711.2% |
| Return on assets (ROA) |
-25.6%
|
-18.9%
|
-20.1% |
| Current ratio |
1286.6%
|
803.9%
|
543.5% |
| Return on equity (ROE) |
-33.4%
|
-25.7%
|
-32.5% |
| Change turnover |
-2,659
|
3,802
|
-18,929 |
| Change turnover % |
-33%
|
80%
|
-79% |
| Chg. No. of employees | |||
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.